https://www.citizen.org/article/letter-to-ohrp-on-canakinumab-ilaris/
Letter to OHRP on Canakinumab (Ilaris) - Public Citizen
Sep 9, 2019 - We hereby request that the Office for Human Research Protections (OHRP) promptly conduct a compliance oversight investigation of an ongoing research study that...
letter toohrpcanakinumabilarispublic
https://www.citizen.org/article/letter-to-ohrp-regarding-testing-the-drug-canakinumab-in-diabetic-children-without-adequate-informed-consent-parental-permission/
Letter to OHRP Regarding Testing the Drug Canakinumab in Diabetic Children Without Adequate...
May 24, 2019 - In a follow-up letter to the Office for Human Research Protections regarding a clinical study testing the drug canakinumab in children with type I diabetes,...
https://www.acc.org/latest-in-cardiology/clinical-trials/2017/08/26/08/35/cantos
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study - American College of Cardiology
Anthony A. Bavry, M.D., M.P.H., FACC
anti inflammatoryamerican collegecanakinumabthrombosisoutcomes
https://www.semanticscholar.org/topic/canakinumab-180-MG-Injection-%5BIlaris%5D/11336442
canakinumab 180 MG Injection [Ilaris] | Semantic Scholar
canakinumab180mginjectionilaris
https://www.foxbusiness.com/features/novartis-sees-positive-phase-iii-results-for-canakinumab
Novartis Sees Positive Phase III Results for Canakinumab | Fox Business
Novartis AG (NOVN.EB) on Sunday said the results of its phase III canakinumab study showed the inflammation treatment could significantly reduce cardiovascular...
phase iiiresults fornovartisseespositive